Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

MINARIK, J., T. PIKA, J. RADOCHA, A. JUNGOVA, J. STRAUB, T. JELINEK, L. POUR, P. PAVLICEK, M. MISTRÍK, L. BROZOVA, P. KRHOVSKA, K. MACHALKOVA, P. JINDRA, I. SPICKA, H. PLONKOVA, M. STORK, J. BACOVSKY, L. CAPKOVA, M. SYKORA, P. KESSLER, L. STEJSKAL, A. HEINDORFER, J. ULLRYCHOVA, T. SKACEL, V. MAISNAR, R. HAJEK: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021, 21(1), 73, ISSN: 1471-2407, PMID: 33451293.